Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Koru Medical Systems Inc (NQ: KRMD )

2.190 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 91,205
Open 2.220
Bid (Size) 2.170 (2)
Ask (Size) 2.190 (3)
Prev. Close 2.190
Today's Range 2.120 - 2.220
52wk Range 1.978 - 4.480
Shares Outstanding 45,710,500
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
From KORU Medical Systems, Inc.
Via Business Wire

Performance

YTD
-7.98%
-7.98%
1 Month
+1.86%
+1.86%
3 Month
+3.30%
+3.30%
6 Month
-6.81%
-6.81%
1 Year
-47.10%
-47.10%

More News

Read More
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
Via InvestorPlace
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference
From KORU Medical Systems, Inc.
Via Business Wire
Recap: KORU Medical Systems Q4 Earnings
Via Benzinga
Earnings Outlook For KORU Medical Systems
Via Benzinga
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance
From KORU Medical Systems, Inc.
Via Business Wire
Earnings Scheduled For March 13, 2024
Via Benzinga
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
From KORU Medical Systems
Via Business Wire
KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference
From KORU Medical Systems
Via Business Wire
KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Participate in Upcoming Investor Conferences
From KORU Medical Systems
Via Business Wire
KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023
From KORU Medical Systems
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors
From KORU Medical Systems, Inc.
Via Business Wire
KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company Showcase
From KORU Medical Systems
Via Business Wire
Breaking The Hospital Chain: Analyst On How KORU's Self-Administered Therapies Promise 20% CAGR Through 2026
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.